Discuss the problem of current conventional response to immunotherapy prediction markers and the need to find novel ones that may enable more patients to benefit from immunotherapy as well as filtering the ones that may not benefit from immunotherapy.

A review article on the mentioned topic to be published in a peer reviewed journal. Article should be up to 5000 words long (including abstract, excluding literature list and tables) and should include 2-3 tables.
Included cancer types: ovarian cancer (especially high grade serous carcinoma, but including others), endometrial carcinoma, other uterine corpus neoplasms (endometrial stromal sarcoma, leiomyosarcoma…), uterine cervix neoplasms (with possible distinction between HPV and non-HPV related), vulvar carcinoma (with possible distinction between HPV and non-HPV related).

Immunotherapy – immune checkpoint blockage inhibitors and other types

The article should include short review on:

– already approved immunotherapies as per FDA and other organizations (EMA, ASCO, ESMO, ESGO and others) with measures of efficacy

– therapies currently being studied in clinical trials with measures of efficacy

Try to at least qualitatively describe the proportion of patients in whom the therapies are effective and whether we see durable responses in them as in sometimes the case with immune checkpoint inhibitors in other types of cancers.

Special focus should be put on markers of response to immunotherapy such as MMR expression, MSI status, PD1/PDL1 expression, tumor mutational burden. Additionally, studies that explored other, novel, emerging markers of response should be thoroughly included with clear description of marker type (for example tissue based – IHC, PCR based, NGS based, microscopy based etc. and possible blood based), correlation with clininical and histopathological data and conventional biomarker status.

The article should discuss the problem of current conventional response to immunotherapy prediction markers and the need to find novel ones that may enable more patients to benefit from immunotherapy as well as filtering the ones that may not benefit from immunotherapy.

Suggested tables in the manuscript:

1. list of immunotherapy agents by cancer type with listed studies, summarized results (e.g. ORR, number of patients) and mentioned any inclusion criteria including markers of response that respresented inclusion criteria (e.g. MMR status, MSI status etc.)

2. list of novel, emerging biomarkers studied with summary of marker type, correlation with clinical and histopathological data and conventional biomarkers.

Example of a pubmed search for studies:

(“Ovarian Neoplasms”[Mesh] OR “Endometrial Neoplasms”[Mesh] OR “Uterine Cervical Neoplasms”[Mesh] OR “Vulvar Neoplasms”[Mesh]) AND “Immune Checkpoint Inhibitors”[Mesh]

Last Completed Projects